ProStrakan Group announced the availability of Abstral (fentanyl) sublingual tablets, a rapidly-disintegrating tablet placed under the tongue for breakthrough cancer pain. It will only be available through the FDA approved Abstral Risk Evaluation and Mitigation Strategy (REMS) program, which community based pharmacies must be enrolled in.

Abstral is available in strengths of 100, 200, 300, 400, 600 and 800mcg.

For more information call (908) 234-1096 visit www.prostrakan.com.